Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats.
Ontology highlight
ABSTRACT: Hyperuricemia is an independent risk factor for renal damage and promotes the progression of chronic kidney disease. In this study, we investigated the effect of I-BET151, a small-molecule inhibitor targeting the bromodomain and extraterminal (BET) proteins, on the development of hyperuricemic nephropathy (HN), and the mechanisms involved. Expression levels of bromodomain-containing protein 2 and 4, but not 3 were increased in the kidney of rats with HN; administration of I-BET151 effectively prevented renal dysfunction, decreased urine microalbumin, and attenuated renal fibrosis as indicated by reduced activation of renal interstitial fibroblasts and expression of fibronectin and collagen I in HN rats. Mechanistic studies show that I-BET151 treatment inhibited transition of renal epitheli
SUBMITTER: Xiong C
PROVIDER: S-EPMC7921804 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA